Related Experiment Video
Updated: Oct 2, 2025

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current
Olga Zajac-Spychala1, Stefanie Kampmeier2, Thomas Lehrnbecher3
1Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznań, Poland.
Insights
Pediatric patients undergoing hematopoietic stem cell transplantation for acute lymphoblastic leukemia face significant infectious risks. This review details strategies for managing these complications to improve patient outcomes.
Area of Science:
- Pediatric Hematology
- Infectious Diseases
- Oncology
Background:
- Hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL) in children leads to profound immunocompromise.
- Patients experience distinct phases of immune reconstitution, each carrying specific infection risks from bacteria, fungi, and viruses.
- Graft-versus-host disease (GvHD) and immunosuppressive therapies further elevate susceptibility to opportunistic infections.
Approach:
- This article reviews current evidence-based recommendations for managing infectious complications post-HSCT for pediatric ALL.
- It covers diagnostic approaches, prophylactic measures, and therapeutic strategies.
- Emphasis is placed on understanding the evolving infectious risks throughout the different phases of immune recovery.
Key Points:
- Early phase (pre-engraftment): Risk of bacterial and fungal infections due to neutropenia and mucosal damage.
- Neutrophil recovery phase: Increased risk of invasive fungal infections and viral reactivation (CMV, VZV, EBV, adenovirus) due to impaired cell-mediated immunity and GvHD treatment.
- Late phase: Continued risk of fungal and viral infections, plus encapsulated bacterial infections, especially with chronic GvHD.
Conclusions:
- Effective management of infectious complications is crucial for reducing morbidity and mortality in pediatric HSCT for ALL.
- Re-establishing immunity through vaccination post-transplant is essential for long-term health.
- Advances in understanding and controlling these infections have significantly improved outcomes over the past two decades.
Abstract:
Haematopoietic stem cell transplantation (HSCT) in paediatric patients with acute lymphoblastic leukaemia (ALL) is associated with a variety of infectious complications which result in significant morbidity and mortality. These patients are profoundly immunocompromised, and immune reconstitution after HSCT generally occurs in astrictly defined order. During the early phase after HSCT until engraftment, patients are at risk of infections due to presence of neutropenia and mucosal damage, with Gramme-positive and Gramme-negative bacteria and fungi being the predominant pathogens. After neutrophil recovery, the profound impairment of cell-mediated immunity and use of glucocorticosteroids for control of graft-vs.-host disease (GvHD) increases the risk of invasive mould infection and infection or reactivation of various viruses, such as cytomegalovirus, varicella zoster virus, Epstein-Barr virus and human adenovirus. In the late phase, characterised by impaired cellular and humoral immunity, particularly in conjunction with chronic GvHD, invasive infections with encapsulated bacterial infections are observed in addition to fungal and viral infections. HSCT also causes a loss of pretransplant naturally acquired and vaccine-acquired immunity; therefore, complete reimmunization is necessary to maintain long-term health in these patients. During the last two decades, major advances have been made in our understanding of and in the control of infectious complications associated with HSCT. In this article, we review current recommendations for the diagnosis, prophylaxis and treatment of infectious complications following HSCT for ALL in childhood.
More Related Videos
03:40Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Regulation of Hematopoietic Stem Cells